Clovis Oncology (CLVSQ) 10-Q 7 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 31, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'CLVS	'
Entity Registrant Name	'CLOVIS ONCOLOGY, INC.	'
Entity Central Index Key	'0001466301	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	33,964,440

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues:	'	'	'	'
License and milestone revenue	'	'	$13,625	'
Operating expenses:	'	'	'	'
Research and development	34,965	16,063	87,556	44,001
General and administrative	5,267	4,312	15,852	11,022
Acquired in-process research and development	'	'	8,806	250
Amortization of intangible asset	'	'	3,409	'
Accretion of contingent purchase consideration	888	'	2,571	'
Total expenses	41,120	20,375	118,194	55,273
Operating loss	-41,120	-20,375	-104,569	-55,273
Other income (expense), net	1,770	55	1,934	-56
Loss before income taxes	-39,350	-20,320	-102,635	-55,329
Income tax expense	-292	'	-2,489	'
Net loss	-39,642	-20,320	-105,124	-55,329
Basic and diluted net loss per common share	($1.17)	($0.68)	($3.10)	($2)
Basic and diluted weighted average common shares outstanding	33,921	30,047	33,871	27,614
Comprehensive loss	($58,809)	($20,299)	($126,126)	($55,314)

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$516,585	$323,228
Prepaid research and development expenses	2,241	976
Other current assets	7,925	4,392
Total current assets	526,751	328,596
Property and equipment, net	2,846	955
Intangible assets	220,723	244,518
Goodwill	68,482	74,811
Other assets	12,725	755
Total assets	831,527	649,635
Current liabilities:	'	'
Accounts payable	2,428	4,420
Accrued research and development expenses	23,832	12,548
Other accrued expenses	4,719	3,984
Total current liabilities	30,979	20,952
Contingent purchase consideration	55,445	55,754
Deferred income taxes, net	69,307	74,955
Convertible senior notes	287,500	'
Other non-current liabilities	6	88
Total liabilities	443,237	151,749
Commitments and contingencies (Note 14)	'	'
Stockholders' equity:	'	'
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2014 and December 31, 2013	'	'
Common stock, $0.001 par value per share, 100,000,000 shares authorized at September 30, 2014 and December 31, 2013; 33,964,065 and 33,897,321 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively	34	34
Additional paid-in capital	778,700	762,170
Accumulated other comprehensive (loss) income	-16,306	4,696
Accumulated deficit	-374,138	-269,014
Total stockholders' equity	388,290	497,886
Total liabilities and stockholders' equity	$831,527	$649,635

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	33,964,065	33,897,321
Common stock, shares outstanding	33,964,065	33,897,321

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Operating activities	'	'
Net loss	($105,124)	($55,329)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	3,772	185
Share-based compensation expense	15,585	6,663
Change in value of contingent purchase consideration	-309	'
Deferred income taxes	761	'
Changes in operating assets and liabilities, net of acquisition of a business:	'	'
Prepaid and accrued research and development expenses	7,152	1,990
Other operating assets	-3,941	-5
Accounts payable	-1,889	-1,463
Other accrued expenses	892	81
Net cash used in operating activities	-83,101	-47,878
Investing activities	'	'
Purchases of property and equipment	-2,191	-80
Net cash used in investing activities	-2,191	-80
Financing activities	'	'
Proceeds from the issuance of convertible senior notes	287,500	'
Proceeds from the sale of common stock, net of issuance costs	'	259,071
Proceeds from exercise of stock options and employee stock purchases	763	1,403
Payment of debt issuance costs	-9,165	'
Net cash provided by financing activities	279,098	260,474
Effect of exchange rate changes on cash and cash equivalents	-449	11
Increase in cash and cash equivalents	193,357	212,527
Cash and cash equivalents at beginning of period	323,228	144,097
Cash and cash equivalents at end of period	$516,585	$356,624

Nature_of_Business_and_Basis_o

Nature of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2014
Nature of Business and Basis of Presentation	'
	1. Nature of Business and Basis of Presentation
	Clovis Oncology, Inc. (the “Company”) commenced operations in May 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and other international markets. The Company has and intends to continue to license or acquire rights to oncology compounds in all stages of development. In exchange for the right to develop and commercialize these compounds, the Company generally expects to provide the licensor with a combination of up-front payments, milestone payments and royalties on future sales. In addition, the Company generally expects to assume the responsibility for future drug development and commercialization costs. The Company currently operates in one segment. Since inception, the Company’s operations have consisted primarily of developing in-licensed compounds, evaluating new product acquisition candidates and general corporate activities. In the first quarter of 2014, the Company exited the development stage, with the recognition of $13.6 million in license and milestone revenue related to its lucitanib collaboration and license agreement with Les Laboratoires Servier (“Servier”). The license and milestone revenue recognized is the first significant revenue from principal operations and therefore, the Company is no longer considered a development stage company.
	Basis of Presentation
	All financial information presented includes the accounts of the Company’s wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments, consisting only of normal recurring adjustments, which in the opinion of management are necessary to fairly state our financial position, results of operations and cash flows for the periods presented. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2013 for a broader discussion of our business and the opportunities and risks inherent in such business.
	Use of Estimates
	The preparation of these financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, revenue and related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to contingent purchase consideration, the allocation of purchase consideration, intangible assets, clinical trial accruals and share-based compensation expense. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.
	Liquidity
	The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through debt and equity financings. Management expects operating losses and negative cash flows to continue for the foreseeable future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and achieving a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless or until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings and may seek additional capital through arrangements with strategic partners or from other sources.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Summary of Significant Accounting Policies	'
	2. Summary of Significant Accounting Policies
	The Company’s significant accounting policies are described in Note 2 of the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 specifies the accounting for revenue from contracts with customers and establishes disclosure requirements relating to the nature, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. This update is effective for annual and interim periods beginning after December 15, 2016 and allows for either full retrospective or modified retrospective adoption. Early adoption is not permitted. The Company is currently evaluating its planned method of adoption and the impact the standard may have on its consolidated financial statements and related disclosures.
	In August 2014, the FASB issued ASU No. 2014-15, “Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern,” which requires management to evaluate whether there are conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern and to provide disclosures when certain criteria are met. The guidance is effective for annual periods beginning in 2016 and interim reporting periods starting in the first quarter of 2017. Early application is permitted. The Company does not expect the standard will have an impact on its disclosures.

EOS_Acquisition

EOS Acquisition	9 Months Ended
	Sep. 30, 2014
EOS Acquisition	'
	3. EOS Acquisition
	On November 19, 2013, the Company acquired all of the outstanding common and preferred stock of Ethical Oncology Science, S.p.A. (“EOS”). The initial purchase consideration was comprised of a cash payment of $11.8 million and the issuance of $173.7 million of the Company’s common stock to the former EOS shareholders. The Company may make additional purchase payments to the previous EOS shareholders if certain lucitanib regulatory and sales milestones are achieved. The range of the potential contingent milestone payments are zero to an estimated maximum of $65.0 million and €115.0 million. The Company recorded a liability for the estimated fair value of these payments, which totaled $55.4 million and $55.8 million at September 30, 2014 and December 31, 2013, respectively.

Financial_Instruments_and_Fair

Financial Instruments and Fair Value Measurement	9 Months Ended
	Sep. 30, 2014
Financial Instruments and Fair Value Measurement	'
	4. Financial Instruments and Fair Value Measurement
	Cash, Cash Equivalents and Marketable Securities
	The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that invest primarily in certificate of deposits, commercial paper and U.S. government and U.S. government agency obligations.
	Marketable securities with original maturities greater than three months are considered to be available-for-sale securities and historically consisted of U.S. agency obligations, U.S. government obligations and corporate debt obligations. Available-for-sale securities are reported at fair value and unrealized gains and losses are included in accumulated other comprehensive income on the Consolidated Balance Sheets. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income (expense), net on the Consolidated Statements of Operations and Comprehensive Loss. The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Investments with maturities beyond one year are classified as short-term based on management’s intent to fund current operations with these securities or to make them available for current operations. A decline in the market value of a security below its cost value that is deemed to be other than temporary is charged to earnings and results in the establishment of a new cost basis for the security.
	Fair Value of Financial Instruments
	Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of inputs that may be used to measure fair value include:
	Level 1:	Quoted prices in active markets for identical assets or liabilities. The Company’s Level 1 assets consist of money market investments. The Company does not have Level 1 liabilities.
	Level 2:	Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company does not have Level 2 assets or liabilities.
	Level 3:	Unobservable inputs that are supported by little or no market activity. The Company does not have Level 3 assets. The contingent purchase consideration related to the undeveloped lucitanib product rights acquired in 2013 with the purchase of EOS is a Level 3 liability. The fair value of this liability is based on unobservable inputs and includes valuations for which there is little, if any, market activity. See Note 3 of the Company’s 2013 Form 10-K for further discussion of the unobservable inputs and valuation techniques related to the contingent purchase consideration liability.
	The following table identifies the Company’s assets and liabilities that were measured at fair value on a recurring basis (in thousands):
		Balance			Level 1		Level 2		Level 3
	September 30, 2014
	Assets:
	Money market	$	447,986		$	447,986	$	—	$	—
	Total assets at fair value	$	447,986		$	447,986	$	—	$	—
	Liabilities:
	Contingent purchase consideration	$	55,445		$	—	$	—	$	55,445
	Total liabilities at fair value	$	55,445		$	—	$	—	$	55,445
	December 31, 2013
	Assets:
	Money market	$	318,886		$	318,886	$	—	$	—
	Total assets at fair value	$	318,886		$	318,886	$	—	$	—
	Liabilities:
	Contingent purchase consideration	$	55,754		$	—	$	—	$	55,754
	Total liabilities at fair value	$	55,754		$	—	$	—	$	55,754
	There were no transfers between Level 1 and Level 2 during the nine months ended September 30, 2014.
	The following table rolls forward the fair value of Level 3 instruments (significant unobservable inputs) in thousands:
		For the Nine
		Months Ended
		September 30, 2014
	Liabilities:
	Balance at beginning of period	$	55,754
	Accretion		2,571
	Change in foreign currency gains and losses		(2,880	)
	Balance at end of period	$	55,445
	The change in the fair value of Level 3 instruments is included in accretion of contingent purchase consideration and other income (expense), net for the change in foreign currency gains and losses on the Consolidated Statements of Operations and Comprehensive Loss.

Other_Current_Assets

Other Current Assets	9 Months Ended
	Sep. 30, 2014
Other Current Assets	'
	5. Other Current Assets
	Other current assets are comprised of the following (in thousands):
		September 30, 2014		December 31, 2013
	Receivable from partners	$	6,544	$	2,921
	VAT recoverable		45		950
	Prepaid expenses and other		1,336		521
	Other current assets	$	7,925	$	4,392

Intangible_Assets_and_Goodwill

Intangible Assets and Goodwill	9 Months Ended
	Sep. 30, 2014
Intangible Assets and Goodwill	'
	6. Intangible Assets and Goodwill
	Intangible acquired in-process research and development (“IPR&D”) assets were established as part of the purchase accounting of EOS in November 2013. The intangible asset balance at September 30, 2014 and December 31, 2013 was $220.7 million and $244.5 million, respectively. The balance decreased $20.4 million over the prior year due to changes in foreign currency translation rates. In addition, the Company recorded a $3.4 million reduction in the intangible assets driven by lower expected future milestone revenue cash flows from our lucitanib development activities due to the receipt of a lucitanib milestone payment from Servier during the first quarter of 2014. This reduction was reported as amortization of intangible asset on the Consolidated Statements of Operations and Comprehensive Loss.
	Recurring amortization of these assets will commence when the useful lives of the intangible assets have been determined. IPR&D intangible assets are evaluated for impairment at least annually or more frequently if impairment indicators exist and any reduction in fair value will be recognized as an expense in the Consolidated Statements of Operations and Comprehensive Loss.
	The acquisition of EOS in November 2013 generated a goodwill balance of $74.8 million at December 31, 2013. This balance decreased to $68.5 million at September 30, 2014 due to changes in foreign currency translation rates.

Other_Accrued_Expenses

Other Accrued Expenses	9 Months Ended
	Sep. 30, 2014
Other Accrued Expenses	'
	7. Other Accrued Expenses
	Other accrued expenses are comprised of the following (in thousands):
		September 30, 2014		December 31, 2013
	Accrued personnel costs	$	3,404	$	3,356
	Accrued corporate legal fees and professional services		132		257
	Accrued expenses – other		1,183		371
	Other accrued expenses	$	4,719	$	3,984

Convertible_Senior_Notes

Convertible Senior Notes	9 Months Ended
	Sep. 30, 2014
Convertible Senior Notes	'
	8. Convertible Senior Notes
	On September 9, 2014, we completed a private placement of $287.5 million aggregate principal amount of 2.5% convertible senior notes due 2021 (the “Notes”) resulting in net proceeds to the Company of $278.3 million after deducting offering expenses. In accordance with the accounting guidance, the conversion feature did not meet the criteria for bifurcation, and the entire principal amount was recorded as a long-term liability on the Consolidated Balance Sheets.
	The Notes are governed by the terms of the indenture between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee. The Notes are senior unsecured obligations and bear interest at a rate of 2.5% per year, payable semi-annually in arrears on March 15 and September 15 of each year, beginning March 15, 2015. The Notes will mature on September 15, 2021, unless earlier converted, redeemed or repurchased.
	Holders may convert all or any portion of the Notes at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the holders will receive shares of our common stock at an initial conversion rate of 16.1616 shares per $1,000 in principal amount of Notes, equivalent to a conversion price of approximately $61.88 per share. The conversion rate is subject to adjustment upon the occurrence of certain events described in the indenture, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date or upon our issuance of a notice of redemption, we will increase the conversion rate for holders who elect to convert the Notes in connection with such a corporate event or during the related redemption period in certain circumstances.
	On or after September 15, 2018, we may redeem the Notes, at our option, in whole or in part, if the last reported sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending not more than two trading days preceding the date on which we provide written notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the Notes.
	If we undergo a fundamental change, as defined in the indenture, prior to the maturity date of the Notes, holders may require us to repurchase for cash all or any portion of the Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.
	The Notes rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the Notes; equal in right of payment to all of our liabilities that are not so subordinated; effectively junior in right of payment to any secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries.
	In connection with the issuance of the Notes, the Company incurred $9.2 million of debt issuance costs, which is included in other assets on the Consolidated Balance Sheets. The debt issuance costs are amortized as interest expense over the expected life of the Notes using the effective interest method. The Company determined the expected life of the debt was equal to the seven-year term of the Notes. As of September 30, 2014, the balance of unamortized debt issuance costs was $9.1 million.
	The fair value of the Notes was $297.3 million at September 30, 2014 and was determined using Level 2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system.
	The following table sets forth total interest expense, included in other income (expense), net on the Consolidated Statements of Operations and Comprehensive Loss, recognized related to the Notes during the three and nine months ended September 30, 2014 (in thousands):
		Three Months Ended		Nine Months Ended
		September 30, 2014		September 30, 2014
	Contractual interest expense	$	439	$	439
	Amortization of debt issuance costs		72		72
	Total interest expense	$	511	$	511

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2014
Stockholders' Equity	'
	9. Stockholders’ Equity
	Common Stock
	In June 2013, the Company sold 3,819,444 shares of its common stock in a public offering at $72.00 per share. The net offering proceeds realized after deducting offering expenses and underwriters’ discounts and commissions were $259.1 million.
	Accumulated Other Comprehensive Income (Loss)
	The accumulated balances related to each component of other comprehensive income (loss) are summarized as follows (in thousands):
		Foreign			Total
		Currency			Accumulated
		Translation			Other
		Adjustments			Comprehensive
					Income (Loss)
	Balance December 31, 2013	$	4,696		$	4,696
	Period change		(21,002	)		(21,002	)
	Balance September 30, 2014	$	(16,306	)	$	(16,306	)
	Balance December 31, 2012	$	53		$	53
	Period change		4,643			4,643
	Balance December 31, 2013	$	4,696		$	4,696
	The period change between December 31, 2013 and September 30, 2014 was primarily due to the currency translation of the IPR&D intangible assets, goodwill and deferred income taxes associated with the acquisition of EOS in November 2013.

ShareBased_Compensation

Share-Based Compensation	9 Months Ended
	Sep. 30, 2014
Share-Based Compensation	'
	10. Share-Based Compensation
	Share-based compensation expense for all equity based programs, including stock options and the employee stock purchase plan, for the three and nine months ended September 30, 2014 and 2013, respectively, was recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss as follows:
		Three Months Ended September 30,					Nine Months Ended September 30,
		2014			2013		2014		2013
	Research and development	$	2,991		$	1,138	$	8,005	$	3,095
	General and administrative		2,445			1,653		7,580		3,568
	Total share-based compensation expense	$	5,436		$	2,791	$	15,585	$	6,663
	The Company did not recognize a tax benefit related to share-based compensation expense during the three and nine months ended September 30, 2014 and 2013, respectively, as the Company maintains net operating loss carryforwards and has established a valuation allowance against the entire net deferred tax asset as of September 30, 2014. No share-based compensation expense was capitalized on our Consolidated Balance Sheets as of September 30, 2014 and December 31, 2013.
	The following table summarizes the activity relating to the Company’s options to purchase common stock for the nine month period ended September 30, 2014:
		Number of			Weighted-		Weighted-		Aggregate
		Options			Average		Average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual
							Term (Years)
	Outstanding at December 31, 2013		2,520,170		$	21.19
	Granted		1,449,457			62
	Exercised		(60,449	)		8.96
	Forfeited		(23,813	)		34.96
	Outstanding at September 30, 2014		3,885,365		$	36.52		8.29	$	64,790,012
	Vested and expected to vest at September 30, 2014		3,620,712		$	35.23		8.22	$	63,341,213
	Vested at September 30, 2014		1,503,631		$	19.47		7.3	$	41,643,182
	The aggregate intrinsic value in the table above represents the pretax intrinsic value, based on our closing stock price of $45.36 as of September 30, 2014, which would have been received by the option holders had all option holders with in-the-money options exercised their options as of that date.
	Presented in the table below are financial details associated with our stock options during the three and nine months ended September 30, 2014 and 2013:
		Three Months Ended September 30,
		2014			2013
	Weighted-average grant-date fair value per share	$	27.85		$	43.43
	Intrinsic value of options exercised	$	4,391		$	85,589
	Cash received from stock option exercises	$	341		$	34,711
		Nine Months Ended September 30,
		2014			2013
	Weighted-average grant-date fair value per share	$	39.13		$	18.43
	Intrinsic value of options exercised	$	2,754,669		$	5,801,963
	Cash received from stock option exercises	$	541,508		$	1,223,023
	As of September 30, 2014, the unrecognized share-based compensation expense related to nonvested options, adjusted for expected forfeitures, was $51.6 million and the estimated weighted-average remaining vesting period was 3.0 years.

License_Agreements

License Agreements	9 Months Ended
	Sep. 30, 2014
License Agreements	'
	11. License Agreements
	Rociletinib (CO-1686)
	In May 2010, the Company entered into a worldwide license agreement with Avila Therapeutics, Inc. (now part of Celgene Corporation) to discover, develop and commercialize a covalent inhibitor of mutant forms of the epidermal growth factor receptor (“EGFR”) gene product. Rociletinib was identified as the lead drug candidate to be developed under the license agreement. The Company is responsible for all preclinical, clinical, regulatory and other activities necessary to develop and commercialize rociletinib. The Company made an up-front payment of $2.0 million upon execution of the license agreement and is obligated to pay royalties on net sales of rociletinib, based on the volume of annual net sales achieved. Celgene has the option to increase royalty rates by electing to reimburse a portion of the development expenses incurred by the Company. This option must be exercised within a limited period of time after Celgene is notified of our intent to pursue regulatory approval of rociletinib in the U.S. or European Union as a first line therapy. Such notice was provided to Celgene on June 4, 2014, and on September 2, 2014, we received notification from Celgene that the company elected not to exercise this option.
	In January 2013, the Company entered into an exclusive license agreement with Gatekeeper Pharmaceuticals, Inc. (“Gatekeeper”) to acquire exclusive rights under patent applications associated with mutant EGFR inhibitors and methods of treatment. Pursuant to the terms of the license agreement, the Company made an up-front payment of $250,000 upon execution of the agreement, which was recognized as acquired in-process research and development expense. If rociletinib is approved for commercial sale, the Company will pay royalties to Gatekeeper on future net sales.
	In February 2014, the Company initiated a Phase II study for rociletinib which resulted in a $5.0 million milestone payment to Celgene as required by the license agreement. This payment was recognized as acquired in-process research and development expense. The Company may be required to pay up to an additional aggregate of $110.0 million in development and regulatory milestone payments if certain clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, the Company may be required to pay up to an aggregate of $120.0 million in sales milestones if certain annual sales targets are achieved.
	Rucaparib
	In June 2011, the Company entered into a worldwide license agreement with Pfizer Inc. to acquire exclusive development and commercialization rights to Pfizer’s drug candidate known as rucaparib. This drug candidate is a small molecule inhibitor of poly (ADP-ribose) polymerase (“PARP”), which the Company is developing for the treatment of selected solid tumors. Pursuant to the terms of the license agreement, the Company made a $7.0 million up-front payment to Pfizer.
	In April 2014, the Company initiated a pivotal registrational study for rucaparib, which resulted in a $0.4 million milestone payment to Pfizer as required by the license agreement. This payment was recognized as acquired in-process research and development expense.
	The Company is responsible for all development and commercialization costs of rucaparib and, if approved, Pfizer will receive royalties on the net sales of the product. In addition, Pfizer is eligible to receive up to $258.5 million of further payments, in aggregate, if certain development, regulatory and sales milestones are achieved.
	In April 2012, the Company entered into a license agreement with AstraZeneca UK Limited to acquire exclusive rights associated with rucaparib under a family of patents and patent applications that claim methods of treating patients with PARP inhibitors in certain indications. The license enables the development and commercialization of rucaparib for the uses claimed by these patents. Pursuant to the terms of the license agreement, the Company made an up-front payment of $250,000 upon execution of the agreement, which was recognized as acquired in-process research and development expense. The Company may be required to pay up to an aggregate of $0.7 million in milestone payments if certain regulatory filings, acceptances and approvals are achieved. If approved, AstraZeneca will also receive royalties on any net sales of rucaparib.
	Lucitanib
	In connection with its November 2013 acquisition of EOS, the Company gained rights to develop and commercialize lucitanib, an oral, selective tyrosine kinase inhibitor. As further described below, EOS licensed the worldwide rights, excluding China, to develop and commercialize lucitanib from Advenchen Laboratories LLC (“Advenchen”). Subsequently, rights to develop and commercialize lucitanib in markets outside the U.S. and Japan were sublicensed by EOS to Servier in exchange for up-front milestone fees, royalties on sales of lucitanib in the sublicensed territories and research and development funding commitments.
	In October 2008, EOS entered into an exclusive license agreement with Advenchen to develop and commercialize lucitanib on a global basis, excluding China. The Company is obligated to pay Advenchen royalties on net sales of lucitanib, based on the volume of annual net sales achieved. In addition, the Company is obligated to pay to Advenchen 25% of any consideration, excluding royalties, received pursuant to any sublicense agreements for lucitanib, including the agreement with Servier. In the first quarter of 2014, the Company recognized acquired in-process research and development expense of $3.4 million, which represents 25% of the sublicense agreement consideration of $13.6 million received from Servier upon the end of opposition and appeal of the lucitanib patent by the European Patent Office.
	In September 2012, EOS entered into a collaboration and license agreement with Servier whereby EOS sublicensed to Servier exclusive rights to develop and commercialize lucitanib in all countries outside of the U.S., Japan and China. In exchange for these rights, EOS received an up-front payment and is entitled to receive additional payments upon achievement of specified development, regulatory and commercial milestones up to €90.0 million in the aggregate. In addition, the Company is entitled to receive sales milestone payments if specified annual sales targets for lucitanib are met, which, in the aggregate, could total €250.0 million. The Company is also entitled to receive royalties on net sales of lucitanib by Servier.
	The development, regulatory and commercial milestones represent non-refundable amounts that would be paid by Servier to the Company if certain milestones are achieved in the future. These milestones, if achieved, are substantive as they relate solely to past performance, are commensurate with estimated enhancement of value associated with the achievement of each milestone as a result of the Company’s performance, which are reasonable relative to the other deliverables and terms of the arrangement, and are unrelated to the delivery of any further elements under the arrangement.
	The Company and Servier are developing lucitanib pursuant to a development plan agreed to between the parties. Servier is responsible for all of the initial global development costs under the agreed upon plan up to €80.0 million. Cumulative global development costs, if any, in excess of €80.0 million will be shared equally between the Company and Servier. Beginning in the third quarter of 2014, depending on the expense type, reimbursements are determined using a standard rate approved by the Company and Servier or actual costs incurred. Previously, reimbursements were determined based on actual costs. Reimbursements are recorded as a reduction to research and development expense in the Consolidated Statements of Operations and Comprehensive Loss.
	The Company recorded a $6.5 million and $2.9 million receivable at September 30, 2014 and December 31, 2013, respectively, for the reimbursable development costs incurred under the global development plan, which is included in other current assets on the Consolidated Balance Sheets. For the three and nine months ending September 30, 2014, we recorded reductions in research and development expense of $4.1 million and $7.9 million, respectively, for reimbursable development costs due from Servier.

Net_Loss_Per_Common_Share

Net Loss Per Common Share	9 Months Ended
	Sep. 30, 2014
Net Loss Per Common Share	'
	12. Net Loss Per Common Share
	Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding using the treasury stock method for the stock options and the if-converted method for the Notes. As a result of our net losses for the periods presented, all potentially dilutive common share equivalents were considered anti-dilutive and were excluded from the computation of diluted net loss per share.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Taxes	'
	13. Income Taxes
	Income tax expense of $2.5 million was recorded during the nine months ended September 30, 2014 due to taxable income earned in a foreign jurisdiction resulting from milestone revenue received during the first quarter of 2014. This expense was partially offset by a deferred tax benefit recognized upon the write down of an intangible asset in the first quarter of 2014 (see Note 6). The Company maintains a valuation allowance against the majority of the net deferred tax assets held at September 30, 2014 and intends to maintain this valuation allowance until there is sufficient evidence that consistent future earnings can be achieved, which is uncertain at this time.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies	'
	14. Commitments and Contingencies
	Royalty and License Fee Commitments
	The Company has entered into certain license agreements, as identified in Note 11, with third parties that include the payment of development and regulatory milestones, as well as royalty payments, upon the achievement of pre-established development, regulatory and commercial targets. The Company’s payment obligation related to these license agreements is contingent upon the successful development, regulatory approval and commercialization of the licensed products. Due to the nature of these arrangements, the future potential payments are inherently uncertain, and accordingly, no amounts have been recorded in the Company’s Consolidated Balance Sheets at September 30, 2014 and December 31, 2013.
	Development and Manufacturing Agreement Commitments
	In February 2013, the Company entered into a development and manufacturing agreement with a third-party supplier for the production of the active ingredient for rucaparib. Under the Development and Manufacturing Agreement, the Company will provide the third-party supplier a rolling 24-month forecast that will be updated by the Company on a quarterly basis. The Company is obligated to order the quantity specified in the first 12 months of any forecast. As of September 30, 2014, no purchase commitments were established under this agreement.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2014
Subsequent Events	'
	15. Subsequent Events
	The Company evaluated events up to the filing date of these interim financial statements and determined that no subsequent activity required disclosure.

Nature_of_Business_and_Basis_o1

Nature of Business and Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2014
Basis of Presentation	'
	Basis of Presentation
	All financial information presented includes the accounts of the Company’s wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments, consisting only of normal recurring adjustments, which in the opinion of management are necessary to fairly state our financial position, results of operations and cash flows for the periods presented. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2013 for a broader discussion of our business and the opportunities and risks inherent in such business.
Use of Estimates	'
	Use of Estimates
	The preparation of these financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, revenue and related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to contingent purchase consideration, the allocation of purchase consideration, intangible assets, clinical trial accruals and share-based compensation expense. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.
Liquidity	'
	Liquidity
	The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through debt and equity financings. Management expects operating losses and negative cash flows to continue for the foreseeable future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and achieving a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless or until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings and may seek additional capital through arrangements with strategic partners or from other sources.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 specifies the accounting for revenue from contracts with customers and establishes disclosure requirements relating to the nature, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. This update is effective for annual and interim periods beginning after December 15, 2016 and allows for either full retrospective or modified retrospective adoption. Early adoption is not permitted. The Company is currently evaluating its planned method of adoption and the impact the standard may have on its consolidated financial statements and related disclosures.
	In August 2014, the FASB issued ASU No. 2014-15, “Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern,” which requires management to evaluate whether there are conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern and to provide disclosures when certain criteria are met. The guidance is effective for annual periods beginning in 2016 and interim reporting periods starting in the first quarter of 2017. Early application is permitted. The Company does not expect the standard will have an impact on its disclosures.
Cash, Cash Equivalents	'
	The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that invest primarily in certificate of deposits, commercial paper and U.S. government and U.S. government agency obligations.
Marketable Securities	'
	Marketable securities with original maturities greater than three months are considered to be available-for-sale securities and historically consisted of U.S. agency obligations, U.S. government obligations and corporate debt obligations. Available-for-sale securities are reported at fair value and unrealized gains and losses are included in accumulated other comprehensive income on the Consolidated Balance Sheets. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income (expense), net on the Consolidated Statements of Operations and Comprehensive Loss. The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Investments with maturities beyond one year are classified as short-term based on management’s intent to fund current operations with these securities or to make them available for current operations. A decline in the market value of a security below its cost value that is deemed to be other than temporary is charged to earnings and results in the establishment of a new cost basis for the security.

Financial_Instruments_and_Fair1

Financial Instruments and Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2014
Assets and Liabilities Measured at Fair Value on Recurring Basis	'
	The following table identifies the Company’s assets and liabilities that were measured at fair value on a recurring basis (in thousands):
		Balance			Level 1		Level 2		Level 3
	September 30, 2014
	Assets:
	Money market	$	447,986		$	447,986	$	—	$	—
	Total assets at fair value	$	447,986		$	447,986	$	—	$	—
	Liabilities:
	Contingent purchase consideration	$	55,445		$	—	$	—	$	55,445
	Total liabilities at fair value	$	55,445		$	—	$	—	$	55,445
	December 31, 2013
	Assets:
	Money market	$	318,886		$	318,886	$	—	$	—
	Total assets at fair value	$	318,886		$	318,886	$	—	$	—
	Liabilities:
	Contingent purchase consideration	$	55,754		$	—	$	—	$	55,754
	Total liabilities at fair value	$	55,754		$	—	$	—	$	55,754
Roll-forward of Fair Value of Level 3 Instruments (significant unobservable inputs)	'
	The following table rolls forward the fair value of Level 3 instruments (significant unobservable inputs) in thousands:
		For the Nine
		Months Ended
		September 30, 2014
	Liabilities:
	Balance at beginning of period	$	55,754
	Accretion		2,571
	Change in foreign currency gains and losses		(2,880	)
	Balance at end of period	$	55,445

Other_Current_Assets_Tables

Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2014
Other Current Assets	'
	Other current assets are comprised of the following (in thousands):
		September 30, 2014		December 31, 2013
	Receivable from partners	$	6,544	$	2,921
	VAT recoverable		45		950
	Prepaid expenses and other		1,336		521
	Other current assets	$	7,925	$	4,392

Other_Accrued_Expenses_Tables

Other Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2014
Other Accrued Expenses	'
	Other accrued expenses are comprised of the following (in thousands):
		September 30, 2014		December 31, 2013
	Accrued personnel costs	$	3,404	$	3,356
	Accrued corporate legal fees and professional services		132		257
	Accrued expenses – other		1,183		371
	Other accrued expenses	$	4,719	$	3,984

Convertible_Senior_Notes_Table

Convertible Senior Notes (Tables)	9 Months Ended
	Sep. 30, 2014
Schedule of Total Interest Expense Included in Other Income (Expense), Net on Consolidated Statements of Operations and Comprehensive Loss Recognized Related to Notes	'
	The following table sets forth total interest expense, included in other income (expense), net on the Consolidated Statements of Operations and Comprehensive Loss, recognized related to the Notes during the three and nine months ended September 30, 2014 (in thousands):
		Three Months Ended		Nine Months Ended
		September 30, 2014		September 30, 2014
	Contractual interest expense	$	439	$	439
	Amortization of debt issuance costs		72		72
	Total interest expense	$	511	$	511

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2014
Component of Other Comprehensive Income (Loss)	'
	The accumulated balances related to each component of other comprehensive income (loss) are summarized as follows (in thousands):
		Foreign			Total
		Currency			Accumulated
		Translation			Other
		Adjustments			Comprehensive
					Income (Loss)
	Balance December 31, 2013	$	4,696		$	4,696
	Period change		(21,002	)		(21,002	)
	Balance September 30, 2014	$	(16,306	)	$	(16,306	)
	Balance December 31, 2012	$	53		$	53
	Period change		4,643			4,643
	Balance December 31, 2013	$	4,696		$	4,696

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2014
Share-Based Compensation Expense Recognized in Accompanying Statements of Operations	'
	Share-based compensation expense for all equity based programs, including stock options and the employee stock purchase plan, for the three and nine months ended September 30, 2014 and 2013, respectively, was recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss as follows:
		Three Months Ended September 30,					Nine Months Ended September 30,
		2014			2013		2014		2013
	Research and development	$	2,991		$	1,138	$	8,005	$	3,095
	General and administrative		2,445			1,653		7,580		3,568
	Total share-based compensation expense	$	5,436		$	2,791	$	15,585	$	6,663
Summary of Stock Options Activity	'
	The following table summarizes the activity relating to the Company’s options to purchase common stock for the nine month period ended September 30, 2014:
		Number of			Weighted-		Weighted-		Aggregate
		Options			Average		Average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual
							Term (Years)
	Outstanding at December 31, 2013		2,520,170		$	21.19
	Granted		1,449,457			62
	Exercised		(60,449	)		8.96
	Forfeited		(23,813	)		34.96
	Outstanding at September 30, 2014		3,885,365		$	36.52		8.29	$	64,790,012
	Vested and expected to vest at September 30, 2014		3,620,712		$	35.23		8.22	$	63,341,213
	Vested at September 30, 2014		1,503,631		$	19.47		7.3	$	41,643,182
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award	'
	Presented in the table below are financial details associated with our stock options during the three and nine months ended September 30, 2014 and 2013:
		Three Months Ended September 30,
		2014			2013
	Weighted-average grant-date fair value per share	$	27.85		$	43.43
	Intrinsic value of options exercised	$	4,391		$	85,589
	Cash received from stock option exercises	$	341		$	34,711
		Nine Months Ended September 30,
		2014			2013
	Weighted-average grant-date fair value per share	$	39.13		$	18.43
	Intrinsic value of options exercised	$	2,754,669		$	5,801,963
	Cash received from stock option exercises	$	541,508		$	1,223,023

Nature_of_Business_and_Basis_o2

Nature of Business and Basis of Presentation - Additional Information (Detail) (USD $)	9 Months Ended	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014
		Les Laboratoires Servier
Nature Of Business [Line Items]	'	'
License and milestone revenue	$13,625	$13,600

EOS_Acquisition_Additional_Inf

EOS Acquisition - Additional Information (Detail)	Sep. 30, 2014	Dec. 31, 2013	Nov. 19, 2013	Sep. 30, 2014	Dec. 31, 2013	Nov. 19, 2013	Nov. 19, 2013	Nov. 19, 2013
	USD ($)	USD ($)	Ethical Oncology Science, S.p.A.	Ethical Oncology Science, S.p.A.	Ethical Oncology Science, S.p.A.	Ethical Oncology Science, S.p.A.	Ethical Oncology Science, S.p.A.	Ethical Oncology Science, S.p.A.
			USD ($)	USD ($)	USD ($)	Regulatory and Sales Milestones	Regulatory and Sales Milestones	Regulatory and Sales Milestones
						Maximum	Maximum	Minimum
						USD ($)	EUR (€)	USD ($)
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'
Business acquisition cash payments made on acquisition	'	'	$11,800,000	'	'	'	'	'
Business acquisition, common stock issued at acquisition date	'	'	173,700,000	'	'	'	'	'
Future potential cash consideration payments	'	'	'	'	'	65,000,000	115,000,000	0
Fair value of contingent consideration	$55,445,000	$55,754,000	'	$55,400,000	$55,800,000	'	'	'

Assets_and_Liabilities_Measure

Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets at fair value	$447,986	$318,886
Contingent purchase consideration	55,445	55,754
Liabilities at fair value	55,445	55,754
Money Market	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets at fair value	447,986	318,886
Fair Value, Inputs, Level 1	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets at fair value	447,986	318,886
Fair Value, Inputs, Level 1 | Money Market	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets at fair value	447,986	318,886
Fair Value, Inputs, Level 3	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Contingent purchase consideration	55,445	55,754
Liabilities at fair value	$55,445	$55,754

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	Sep. 30, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Transfers between Level 1 and Level 2	$0

Rollforward_of_Fair_Value_of_L

Roll-forward of Fair Value of Level 3 Instruments (significant unobservable inputs) (Detail) (Fair Value, Inputs, Level 3, USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014
Fair Value, Inputs, Level 3	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Balance at beginning of period	$55,754
Accretion	2,571
Change in foreign currency gains and losses	-2,880
Balance at end of period	$55,445

Other_Current_Assets_Detail

Other Current Assets (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Other Current Assets [Line Items]	'	'
Receivable from partners	$6,544	$2,921
VAT recoverable	45	950
Prepaid expenses and other	1,336	521
Other current assets	$7,925	$4,392

Intangible_Assets_and_Goodwill1

Intangible Assets and Goodwill - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Intangible Assets And Goodwill [Line Items]	'	'
Intangible assets	$220,723,000	$244,518,000
Decrease in intangible assets due to changes in foreign currency translation rates	-20,400,000	'
Impairment charges for intangible assets	3,409,000	'
Goodwill	68,482,000	74,811,000
In Process Research and Development	'	'
Intangible Assets And Goodwill [Line Items]	'	'
Intangible assets	220,700,000	244,500,000
Ethical Oncology Science, S.p.A.	'	'
Intangible Assets And Goodwill [Line Items]	'	'
Goodwill	$68,500,000	$74,800,000

Other_Accrued_Expenses_Detail

Other Accrued Expenses (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Liabilities [Line Items]	'	'
Accrued personnel costs	$3,404	$3,356
Accrued corporate legal fees and professional services	132	257
Accrued expenses - other	1,183	371
Other accrued expenses	$4,719	$3,984

Convertible_Senior_Notes_Addit

Convertible Senior Notes - Additional Information (Detail) (USD $)	0 Months Ended	9 Months Ended
	Sep. 09, 2014	Sep. 30, 2014	Sep. 09, 2014
	D	D
Debt Instrument [Line Items]	'	'	'
Convertible senior notes, aggregate principal amount	'	$287,500,000	'
Net proceeds form convertible senior notes	'	287,500,000	'
Convertible Senior Unsecured Notes	'	'	'
Debt Instrument [Line Items]	'	'	'
Convertible senior notes, aggregate principal amount	'	'	287,500,000
Convertible senior notes, interest rate	'	'	2.50%
Net proceeds form convertible senior notes	278,300,000	'	'
Convertible senior notes, frequency of periodic payment	'	'Semi-annually	'
Debt instrument, beginning date of periodic payment	'	15-Mar-15	'
Convertible senior notes, maturity date	'	15-Sep-21	'
Convertible senior notes, initial conversion price per share	'	'	$61.88
Common stock initial conversion rate per $1,000 in principal amount	16.1616	'	'
Last reported sale price of common stock	150.00%	'	'
Debt instrument, conversion in effect for number of trading days	20	'	'
Debt instrument conversion, consecutive trading day period	'30 days	'	'
Debt instrument redemption price percentage to principal amount	100.00%	'	'
Debt instrument redemption description	'	'On or after September 15, 2018, we may redeem the Notes, at our option, in whole or in part, if the last reported sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending not more than two trading days preceding the date on which we provide written notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date.	'
Debt instrument, redemption period start date	'	15-Sep-18	'
Debt instrument, trading days preceding redemption notice, maximum	'	2	'
Debt instrument repurchase percentage	'	100.00%	'
Debt issuance costs	'	9,200,000	'
Debt instrument term	'	'7 years	'
Unamortized debt issuance costs	'	9,100,000	'
Convertible Senior Unsecured Notes | Semi Annual Payment, First payment date	'	'	'
Debt Instrument [Line Items]	'	'	'
Interest payment date on senior notes	'	'--03-15	'
Convertible Senior Unsecured Notes | Semi Annual Payment, Second payment date	'	'	'
Debt Instrument [Line Items]	'	'	'
Interest payment date on senior notes	'	'--09-15	'
Convertible Senior Unsecured Notes | Fair Value, Inputs, Level 2	'	'	'
Debt Instrument [Line Items]	'	'	'
Debt instrument, fair value	'	$297,300,000	'

Schedule_of_Total_Interest_Exp

Schedule of Total Interest Expense Included in Other Income (Expense), Net on Consolidated Statements of Operations and Comprehensive Loss Recognized Related to Notes (Detail) (USD $)	3 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014
Debt Instrument [Line Items]	'	'
Contractual interest expense	$439	$439
Amortization of debt issuance costs	72	72
Total interest expense	$511	$511

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	9 Months Ended		1 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2014	Jun. 30, 2013
			Common Stock
Class of Stock [Line Items]	'	'	'
Common stock, shares issued	'	'	3,819,444
Sale of stock price per share	'	$45.36	$72
Proceeds from the sale of common stock, net of issuance costs	$259,071	'	$259,100

Component_of_Other_Comprehensi

Component of Other Comprehensive Income (Loss) (Detail) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'
Beginning balance	$4,696	$53
Period change	-21,002	4,643
Ending balance	-16,306	4,696
Foreign Currency Translation Adjustments	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'
Beginning balance	4,696	53
Period change	-21,002	4,643
Ending balance	($16,306)	$4,696

ShareBased_Compensation_Expens

Share-Based Compensation Expense Recognized in Accompanying Statements of Operations (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based compensation expense	$5,436	$2,791	$15,585	$6,663
Research and development	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based compensation expense	2,991	1,138	8,005	3,095
General and administrative	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based compensation expense	$2,445	$1,653	$7,580	$3,568

ShareBased_Compensation_Additi

Share-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Share-based compensation expense, tax benefit recognized	$0	$0	$0	$0	'
Capitalized share-based compensation expense	'	'	0	'	0
Closing stock price	$45.36	'	$45.36	'	'
Unrecognized stock-based compensation expense related to nonvested options	$51,600,000	'	$51,600,000	'	'
Unrecognized stock-based compensation expense related to nonvested options, weighted-average remaining vesting period	'	'	'3 years	'	'

Summary_of_Stock_Options_Activ

Summary of Stock Options Activity (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Beginning Balance, Number of Options Outstanding	2,520,170
Granted, Number of Options Outstanding	1,449,457
Exercised, Number of Options Outstanding	-60,449
Forfeited, Number of Options Outstanding	-23,813
Ending Balance, Number of Options Outstanding	3,885,365
Vested and expected to vest, Number of Options Outstanding	3,620,712
Vested, Number of Options Outstanding	1,503,631
Beginning Balance, Weighted Average Exercise Price	$21.19
Granted, Weighted Average Exercise Price	$62
Exercised, Weighted Average Exercise Price	$8.96
Forfeited, Weighted Average Exercise Price	$34.96
Ending Balance, Weighted Average Exercise Price	$36.52
Vested and expected to vest, Weighted Average Exercise Price	$35.23
Vested, Weighted Average Exercise Price	$19.47
Outstanding, Weighted Average Remaining Contractual Term (Years)	'8 years 3 months 15 days
Vested and expected to vest, Weighted Average Remaining Contractual Term (Years)	'8 years 2 months 19 days
Vested, Weighted Average Remaining Contractual Term (Years)	'7 years 3 months 18 days
Outstanding, Aggregate Intrinsic Value	$64,790,012
Vested and expected to vest, Aggregate Intrinsic Value	63,341,213
Vested, Aggregate Intrinsic Value	$41,643,182

Schedule_of_ShareBased_Compens

Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Weighted-average grant-date fair value per share	$27.85	$43.43	$39.13	$18.43
Intrinsic value of options exercised	$4,391	$85,589	$2,754,669	$5,801,963
Cash received from stock option exercises	$341	$34,711	$541,508	$1,223,023

License_Agreements_Additional_

License Agreements - Additional Information (Detail)

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2012

Sep. 30, 2014

Mar. 31, 2014

Sep. 30, 2014

Dec. 31, 2013

Feb. 28, 2014

Apr. 30, 2014

Sep. 30, 2014

Apr. 30, 2012

Oct. 31, 2008

Mar. 31, 2014

31-May-10

Jan. 31, 2013

Jun. 30, 2011

Apr. 30, 2012

Feb. 28, 2014

USD ($)

USD ($)

USD ($)

Les Laboratoires Servier

Les Laboratoires Servier

Les Laboratoires Servier

Les Laboratoires Servier

Les Laboratoires Servier

License Agreement Terms

License Agreement Terms

License Agreement Terms

License Agreement Terms

License Agreement Terms

License Agreement Terms

Up-front license payment

Up-front license payment

Up-front license payment

Up-front license payment

Regulatory Milestone Payment

EUR (€)

USD ($)

USD ($)

USD ($)

USD ($)

License Agreements Licensor Avila Therapeutics

License Agreements Licensor Pfizer

License Agreements Licensor Pfizer

License Agreements Licensor Astra Zeneca U K Ltd

Advenchen Laboratories LLC

Advenchen Laboratories LLC

License Agreement Terms

License Agreement Terms

License Agreement Terms

License Agreement Terms

License Agreement Terms

Name of drug product in-licensed by the entity - Rociletinib

Rucaparib

Rucaparib

Rucaparib

USD ($)

License Agreements Licensor Avila Therapeutics

License Agreements Licensor Gatekeeper

License Agreements Licensor Pfizer

License Agreements Licensor Astra Zeneca U K Ltd

License Agreements Licensor Avila Therapeutics

USD ($)

USD ($)

USD ($)

USD ($)

Name of drug product in-licensed by the entity - Rociletinib

Name of drug product in-licensed by the entity - Rociletinib

Rucaparib

Rucaparib

Name of drug product in-licensed by the entity - Rociletinib

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Research and Development Arrangement, Contract to Perform for Others [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Up-front payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,000,000

$250,000

$7,000,000

$250,000

'

Acquired in process research and development costs

8,806,000

250,000

'

'

'

'

'

'

'

400,000

'

'

'

3,400,000

'

'

'

'

5,000,000

Future expected development and regulatory payment

'

'

'

'

'

'

'

'

110,000,000

'

'

700,000

'

'

'

'

'

'

'

Sales milestone payments

'

'

'

'

'

'

'

'

120,000,000

'

'

'

'

'

'

'

'

'

'

Future expected development, regulatory and sales milestone payments

'

'

'

'

'

'

'

'

'

'

258,500,000

'

'

'

'

'

'

'

'

Percentage of Non-Royalty Consideration Payable on Sublicense Agreements

'

'

'

'

'

'

'

'

'

'

'

'

25.00%

'

'

'

'

'

'

Sublicense agreement consideration

13,625,000

'

'

'

'

13,600,000

'

'

'

'

'

'

'

13,600,000

'

'

'

'

'

Additional payments receivable on achievement

'

'

'

90,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional payments receivable on attaining the sales target

'

'

'

250,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial global development costs reimbursable

'

'

'

80,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Development cost receivable

6,544,000

'

2,921,000

'

6,500,000

'

6,500,000

2,900,000

'

'

'

'

'

'

'

'

'

'

'

Reduction in research and development expense for reimbursable development costs due from Servier

'

'

'

'

$4,100,000

'

$7,900,000

'

'

'

'

'

'

'

'

'

'

'

'

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014
Income Taxes [Line Items]	'	'
Income tax expense	$292	$2,489

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	1 Months Ended
	Feb. 28, 2013	Sep. 30, 2014
Purchase Commitment, Excluding Long-term Commitment [Line Items]	'	'
Purchase commitment	'	$0
Contractual agreement quarterly forecasts required period	'24 months	'
Contractual agreement obligated forecast period	'12 months	'